Acubiosys
Acubiosys is a biotechnology organization headquartered in Hyderabad, dedicated to scientific research and development in drug discovery and development. They focus on innovative, science-first approaches to create therapies that improve lives, utilizing cutting-edge science, nanotechnology, and AI-driven strategies. Their mission is to develop novel therapeutic approaches and support various phases of drug discovery, from early research to lead optimization, with a commitment to quality, collaboration, and innovation.
Industries
Nr. of Employees
small (1-50)
Acubiosys
Plot No – D -14/A, Moulali, Industrial area, Moula Ali, Hyderabad, – 500040 Telangana, India
Products
Fixed-dose dermal formulation for psoriasis (research-stage)
A topical fixed-dose dermal formulation combining an existing clinical candidate with phytopharmaceutical ingredients formulated with nano-delivery approaches; reported to reduce inflammatory markers in in vitro and to improve clinical severity indices in an imiquimod-induced psoriasis mouse model. GMP formulation development and clinical progression were described as ongoing.
Fixed-dose dermal formulation for psoriasis (research-stage)
A topical fixed-dose dermal formulation combining an existing clinical candidate with phytopharmaceutical ingredients formulated with nano-delivery approaches; reported to reduce inflammatory markers in in vitro and to improve clinical severity indices in an imiquimod-induced psoriasis mouse model. GMP formulation development and clinical progression were described as ongoing.
Services
Standardized and customized in vitro ADME/T assays including solubility, permeability (PAMPA), metabolic clearance, CYP/UGT assays, plasma protein binding, cytotoxicity and genotoxicity to support hit-to-lead and lead optimization.
Preclinical PK/TK study design and execution across multiple species and dosing formats, including cannulation, serial sampling, tissue distribution, bile excretion and mass-balance studies.
Early toxicology services including dose range finding, MTD, non-GLP repeated-dose toxicity, toxicokinetics and tissue analysis to de-risk preclinical candidates.
In vitro DDI study design and execution following regulatory guidance, including CYP/UGT inhibition, time-dependent inhibition and transporter interaction studies.
Rapid LC–MS/MS method development, validation and quantitative analysis of small molecules and biomarkers across multiple biological matrices with GLP-like QA/QC.
Pre-formulation, formulation design and optimization for NCEs, generics, herbal and nutraceutical products including topical, nasal, inhalation and oral dosage forms and novel/nano delivery approaches.
Standardized and customized in vitro ADME/T assays including solubility, permeability (PAMPA), metabolic clearance, CYP/UGT assays, plasma protein binding, cytotoxicity and genotoxicity to support hit-to-lead and lead optimization.
Preclinical PK/TK study design and execution across multiple species and dosing formats, including cannulation, serial sampling, tissue distribution, bile excretion and mass-balance studies.
Early toxicology services including dose range finding, MTD, non-GLP repeated-dose toxicity, toxicokinetics and tissue analysis to de-risk preclinical candidates.
In vitro DDI study design and execution following regulatory guidance, including CYP/UGT inhibition, time-dependent inhibition and transporter interaction studies.
Rapid LC–MS/MS method development, validation and quantitative analysis of small molecules and biomarkers across multiple biological matrices with GLP-like QA/QC.
Pre-formulation, formulation design and optimization for NCEs, generics, herbal and nutraceutical products including topical, nasal, inhalation and oral dosage forms and novel/nano delivery approaches.
Expertise Areas
- Preclinical ADME/T and DMPK
- In vivo pharmacokinetics and toxicokinetics
- Exploratory toxicology and non-GLP studies
- Formulation development and novel drug delivery (nanoformulations)
Key Technologies
- LC–MS/MS quantitative bioanalysis
- HPLC–MS/MS degradation and metabolite identification
- PAMPA permeability assays
- Franz diffusion cell (skin permeability)
News & Updates
Discussion on the latest therapies for psoriasis in 2024 and beyond.
Exploring the role of AI and ML in drug metabolism and pharmacokinetics.
Insights into humanized mouse models for biomedical research.
Discussion on the emerging paradigm of targeted protein degradation.
How AI is transforming drug discovery processes.
An overview of the latest research and therapies for psoriasis in 2024 and beyond.
Discussion on the latest therapies for psoriasis in 2024 and beyond.
Exploring the role of AI and ML in drug metabolism and pharmacokinetics.
Insights into humanized mouse models for biomedical research.
Discussion on the emerging paradigm of targeted protein degradation.
How AI is transforming drug discovery processes.
An overview of the latest research and therapies for psoriasis in 2024 and beyond.